SuperworthPfizer profit margin PFE
Gross, operating and net profit as a share of revenue over the last twelve months, from 2009.
- Net margin, 12 months
- 6.8%
- Operating margin, 12 months
- 21.7%
- Net margin on a year earlier
- −10.0 pts
- Peer median
- 9.8%
Over the twelve months to Jun 28, 2026, Pfizer kept 6.8% of its revenue as net profit, with an operating margin of 21.7% and a gross margin of 73.2%.
Five years earlier its net margin was 22.7%.
The median for 8 large drugmakers of a similar size is 9.8%.
Profit margin over time
Fiscal year by fiscal year
| Fiscal year | Net margin | Operating margin | Gross margin |
|---|---|---|---|
| FY2025 | 12.4% | 22.8% | 74.3% |
| FY2024 | 12.6% | 19.5% | 71.9% |
| FY2023 | 3.6% | 2.1% | 58.1% |
| FY2022 | 31.3% | 34.8% | 65.8% |
| FY2021 | 27.0% | 23.9% | 62.1% |
| FY2020 | 21.4% | 19.8% | 79.6% |
| FY2019 | 31.4% | 41.1% | 80.3% |
| FY2018 | 20.8% | 26.1% | 79.0% |
| FY2017 | 40.6% | 26.1% | 78.6% |
| FY2016 | 13.7% | 22.7% | 76.7% |
| FY2015 | 14.2% | 24.2% | 80.3% |
| FY2014 | 18.4% | 26.7% | 80.7% |
| FY2013 | 42.7% | 29.4% | 81.4% |
| FY2012 | 25.6% | 27.5% | 81.4% |
| FY2011 | 15.1% | 22.7% | 78.0% |
Quarter by quarter
| Quarter | Ended | Net margin, 12 months | Change on a year | Operating margin |
|---|---|---|---|---|
| Q2 FY26 | 6.8% | −10.0 pts | 21.7% | |
| Q1 FY26 | 11.8% | −0.8 pts | 23.0% | |
| Q4 FY25 | 12.4% | −0.2 pts | 22.8% | |
| Q3 FY25 | 15.7% | +8.6 pts | 21.9% | |
| Q2 FY25 | 16.8% | +21.5 pts | 23.2% | |
| Q1 FY25 | 12.6% | +13.2 pts | 19.3% | |
| Q4 FY24 | 12.6% | +9.1 pts | 19.5% | |
| Q3 FY24 | 7.0% | −8.1 pts | 9.6% | |
| Q2 FY24 | −4.6% | −32.0 pts | −4.2% | |
| Q1 FY24 | −0.6% | −31.7 pts | −2.1% | |
| Q4 FY23 | 3.6% | −27.7 pts | 2.1% | |
| Q3 FY23 | 15.1% | −14.7 pts | 14.4% |
Against its peers
Companies in Drug Manufacturers - General nearest Pfizer's size, closest first, today.
| Company | Profit margin |
|---|---|
| PFEPfizer | 6.8% |
| GILDGilead Sciences | −10.6% |
| BMYBristol-Myers Squibb | 18.9% |
| AMGNAmgen | 23.0% |
| MRKMerck | 4.8% |
| ABBVAbbVie | 9.8% |
| JNJJohnson & Johnson | n/m |
| BIIBBiogen | 8.3% |
| LLYEli Lilly and | 33.5% |
| Peer median | 9.8% |
Where Pfizer ranks
What the profit margin tells you
Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).
Compare within an industry. 10% is superb for a retailer and poor for a software company.
More on Pfizer
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.